KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $18.1 million.

  • Fulgent Genetics' Accounts Payables fell 866.95% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year decrease of 866.95%. This contributed to the annual value of $18.4 million for FY2024, which is 1955.73% up from last year.
  • Fulgent Genetics' Accounts Payables amounted to $18.1 million in Q3 2025, which was down 866.95% from $18.9 million recorded in Q2 2025.
  • Fulgent Genetics' 5-year Accounts Payables high stood at $37.1 million for Q2 2022, and its period low was $14.5 million during Q3 2022.
  • Moreover, its 5-year median value for Accounts Payables was $19.6 million (2024), whereas its average is $20.1 million.
  • In the last 5 years, Fulgent Genetics' Accounts Payables skyrocketed by 51085.81% in 2021 and then tumbled by 4446.9% in 2023.
  • Over the past 5 years, Fulgent Genetics' Accounts Payables (Quarter) stood at $20.5 million in 2021, then increased by 12.68% to $23.1 million in 2022, then crashed by 33.49% to $15.4 million in 2023, then grew by 19.56% to $18.4 million in 2024, then decreased by 1.5% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $18.9 million for Q2 2025, and $18.2 million during Q1 2025.